Literature DB >> 5794243

The discrimination of phenotypes for rate of disappearance of isonicotinoyl hydrazide from serum.

E M Scott, R C Wright, D D Weaver.   

Abstract

Expression of the rate of inactivation of isonicotinoyl hydrazide (INH) as a first-order constant gave better discrimination of slow and rapid inactivators than did the level of INH at the end of 6 hr. The most probable division point between the two classes was at k = 0.130. Rate of inactivation by obligatory heterozygotes was determined. Such heterozygotes could not be adequately differentiated from homozygous rapid inactivators. The gene frequency for slow inactivation was 0.46 +/-0.04 in Alaskan Eskimos and 0.62+/-0.06 in Athabaskan Indians.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5794243      PMCID: PMC322338          DOI: 10.1172/JCI106081

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  6 in total

1.  GENETICS OF ISONIAZID METABOLISM IN CAUCASIAN, NEGRO, AND JAPANESE POPULATIONS.

Authors:  A P DUFOUR; R A KNIGHT; H W HARRIS
Journal:  Science       Date:  1964-07-24       Impact factor: 47.728

2.  Genetical and geographic studies on isoniazid inactivation.

Authors:  S SUNAHARA
Journal:  Science       Date:  1961-11-10       Impact factor: 47.728

3.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

4.  A comparison between the behavior of Eskimos and non-Eskimos to the administration of isoniazid.

Authors:  A R ARMSTRONG; H E PEART
Journal:  Am Rev Respir Dis       Date:  1960-04

5.  Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method.

Authors:  J W JENNE
Journal:  Am Rev Respir Dis       Date:  1960-01

6.  Fluorometric determination of isonicotinic acid hydrazide in serum.

Authors:  E M Scott; R C Wright
Journal:  J Lab Clin Med       Date:  1967-08
  6 in total
  9 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  A filter paper method for determining isoniazid acetylator phenotype.

Authors:  W W Weber; W Brenner
Journal:  Am J Hum Genet       Date:  1974-07       Impact factor: 11.025

3.  Inactivation of isoniazid by Canadian Eskimos and Indians.

Authors:  C W Jeanes; O Schaefer; L Eidus
Journal:  Can Med Assoc J       Date:  1972-02-19       Impact factor: 8.262

4.  Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution.

Authors:  A K Karim; M S Elfellah; D A Evans
Journal:  J Med Genet       Date:  1981-10       Impact factor: 6.318

5.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

7.  Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Authors:  T B Vree; W J O'Reilly; Y A Hekster; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

8.  Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.

Authors:  Y Horai; T Ishizaki; T Sasaki; G Koya; K Matsuyama; S Iguchi
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

9.  Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.

Authors:  G A Ellard; P T Gammon
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.